The evolution of GBS resistance to macrolides/lincosamides shows an increasing trend during the last decade in the USA, up to 54.8%/43.2% [ 53 ], and in most European countries such as Bulgaria (58.88%/15.89%) [ 17 ], Denmark (23.8%/26%) [ 4 , 58 ], Portugal (16.1–35.1%/14.2–33.9%) [ 59 , 60 ], and Serbia (23.1–26.7%/22.1%) [ 12 , 54 ].
← all excerpts
A Review of the Impact of Streptococcal Infections and Antimicrobial Resistance on Human Health.
1
—
—